Heparin Drip: What It Is, Uses, and Side Effects

A heparin drip is a continuous intravenous infusion of unfractionated heparin, a blood-thinning medication used to prevent and treat dangerous blood clots. It remains one of the most commonly administered drugs in hospital settings, particularly in intensive care units and cardiac wards. What makes it distinctive among anticoagulants is a combination of rapid onset, short duration of action, and the ability to fine-tune its dose in real time, though those same properties demand constant lab monitoring and careful nursing oversight.

How Heparin Works Inside the Body

Heparin does not dissolve clots that have already formed. Instead, it supercharges a natural protein in your blood called antithrombin, which normally circulates in a somewhat sluggish state. Once heparin binds to antithrombin, that protein becomes far more efficient at shutting down the clotting enzymes thrombin and factor Xa. The net effect is that your blood’s ability to form new clots drops sharply, and existing clots are less likely to grow.

Because heparin is given directly into a vein, it starts working within minutes. Its half-life is short, roughly an hour and a half, and the drug is cleared primarily by cells in the liver and spleen rather than by the kidneys.¹ That short half-life is actually a feature rather than a flaw: if you start bleeding or need emergency surgery, the medical team can stop the drip and your clotting ability rebounds quickly. When even faster reversal is needed, a drug called protamine can neutralize heparin almost immediately.

What a Heparin Drip Is Used For

The drip serves two broad categories of patients: people with blood clots and people at high risk of forming them. Within those categories, the specific situations are varied.

Blood Clots in the Legs and Lungs

Intravenous heparin is considered the initial treatment of choice for most patients with acute deep vein thrombosis in the proximal leg veins or pulmonary embolism. The goal is not to break up the clot but to halt its growth and prevent pieces from breaking off and traveling to the lungs. Randomized trials have shown that when the drip achieves an adequate anticoagulant response, the risk of a recurrent clotting event drops to around 2%, compared with roughly 25% when anticoagulation falls short of the target range.² Once the immediate danger passes, patients are typically transitioned to an oral blood thinner for longer-term protection.

Heart Attacks and Unstable Angina

Heparin drips are widely used in acute coronary syndromes, including heart attacks and unstable angina. In a heart attack caused by a complete blockage of a coronary artery, the drip often runs alongside clot-busting drugs or after a stent placement to keep the newly opened vessel from clotting shut again. Guidelines from the American College of Cardiology and American Heart Association recommend weight-based dosing: an initial bolus calculated per kilogram of body weight, followed by a continuous infusion adjusted to keep clotting times in a therapeutic window.³ The doses and targets differ depending on whether the patient is also receiving clot-dissolving medication.

Other Hospital Uses

Beyond clots and heart attacks, heparin drips show up in several other settings. Patients on dialysis may receive heparin to prevent clotting in the circuit. People undergoing certain heart and vascular surgeries receive it during the procedure. And in some critically ill patients who cannot take oral medications, a heparin infusion serves as a bridge until they can swallow a pill-form anticoagulant.

Dosing and How It Gets Adjusted

A heparin drip is not a set-it-and-forget-it medication. Dosing starts with a weight-based calculation, and many hospitals use standardized nomograms that guide nurses through the initial bolus and infusion rate. These protocols have been shown to get patients into the therapeutic range faster. One large academic medical center found that implementing a weight-based, nurse-driven nomogram cut the average time to reach therapeutic anticoagulation from about 19 hours down to about 12 hours, and the percentage of patients reaching their target within 24 hours rose from roughly 74% to nearly 89%.⁴

Once the drip is running, a blood test is drawn every six hours (or at intervals specified by the nomogram) and the infusion rate is dialed up or down based on the result. The dose may change several times in the first day alone. Because of how precisely heparin must be managed, hospitals typically require a two-person verification before the drug is administered or the rate is changed, with a second nurse or physician independently confirming the dose.⁵

Monitoring the Drip

Getting heparin into the therapeutic sweet spot matters enormously. Too little and clots can recur; too much and the patient bleeds. Hospitals traditionally track the effect using a blood test called the activated partial thromboplastin time, or aPTT. The target is typically 1.5 to 2.5 times the normal baseline value. A growing number of hospitals have shifted to a different test, the anti-factor Xa assay, which measures heparin’s activity more directly.

The two tests do not always agree. Studies comparing them have found discordance rates between roughly 49% and 57%, meaning that for about half of all blood draws, one test says the patient is in range while the other says they are not.⁶⁷ This is not just a laboratory curiosity. In one study, patients monitored with the anti-Xa assay spent considerably more time in the therapeutic range: 57% of patients achieved their goal more than half the time, compared to only 10% of those monitored by aPTT alone.⁷ The aPTT can be thrown off by factors unrelated to heparin, including liver disease, lupus antibodies, and elevated clotting factor levels, which partly explains why the anti-Xa approach often keeps patients closer to the intended range.

One comparison that included 90 paired samples found that while the two tests correlated reasonably well overall, the interpretive categories still disagreed: when anti-Xa levels were in the therapeutic range, aPTT readings were subtherapeutic 60% of the time and above the therapeutic range 13% of the time.⁸ This practical gap is why many large hospitals are transitioning to anti-Xa-based protocols, though the older aPTT method remains widespread.

Bleeding, the Most Common Side Effect

Any drug that impairs clotting can cause bleeding, and heparin is no exception. Bleeding is the most frequent serious side effect of a heparin drip. It can range from minor nuisances like oozing from an IV site or easy bruising to life-threatening events such as gastrointestinal hemorrhage or bleeding into the brain.

Who bleeds and who doesn’t is not random. Research analyzing patients treated for acute blood clots identified several independent risk factors: poor overall functional status was the strongest predictor, followed by a personal history of bleeding problems, recent surgery or trauma, and larger body surface area.⁹ On the drug side, higher doses and anti-Xa levels above 0.8 units per milliliter were both associated with increased major bleeding, and the dose effect persisted even after accounting for the measured drug level.⁹ In practical terms, this means tight monitoring and quick dose adjustments are the main defense against serious hemorrhage.

If bleeding does occur, the first step is stopping or reducing the infusion. Because heparin’s half-life is so short, the anticoagulant effect begins to fade within minutes. For severe or urgent bleeding, protamine sulfate can be given intravenously to neutralize the heparin almost immediately. Protamine works well but carries its own risks, including allergic reactions, so it is reserved for situations where the bleeding cannot wait for the drug to wear off on its own.

Heparin-Induced Thrombocytopenia

Among the side effects unique to heparin, heparin-induced thrombocytopenia, known as HIT, stands out as the most dangerous and the most counterintuitive. Rather than simply causing bleeding, HIT triggers a paradoxical state where the platelet count plummets and the patient simultaneously becomes more likely to form clots, not less. This happens because the immune system produces antibodies that recognize complexes of heparin and a platelet protein called platelet factor 4. Those antibodies bind to platelets and activate them, consuming platelets (driving the count down) while simultaneously revving up the clotting cascade.¹⁰

HIT typically appears 5 to 10 days after heparin is started, though it can occur sooner in patients who have been exposed to heparin within the previous few months and still carry circulating antibodies. The hallmark sign is a drop in platelet count of 50% or more from baseline. But because hospitalized patients can have low platelets for many reasons, from infections to other medications, diagnosing HIT requires careful clinical reasoning.

Most hospitals use a scoring tool called the 4Ts score to gauge the likelihood of HIT before sending lab tests. A systematic review and meta-analysis across 13 studies involving more than 3,000 patients found that a low-probability 4Ts score had a negative predictive value of essentially 100%, meaning it is very reliable at ruling HIT out. However, an intermediate score correctly predicted HIT only about 14% of the time, and even a high score was confirmed only about 64% of the time.¹¹ So the 4Ts score is best at telling you when it is safe to continue heparin, rather than confirming HIT is present. When suspicion is intermediate or high, blood is sent for antibody testing and the heparin drip is stopped immediately.

Stopping heparin alone is not enough if HIT is suspected, because the prothrombotic state persists even after the drug is gone. Patients are switched to an alternative anticoagulant from a different drug class. Direct thrombin inhibitors such as argatroban have been studied specifically for this scenario and are the standard replacement.¹²

Less Well-Known Side Effects

Beyond bleeding and HIT, a heparin drip can cause a handful of other problems that patients and even some clinicians may not immediately associate with the drug.

One of these is elevated potassium levels. Heparin can suppress the adrenal hormone aldosterone, which normally helps the kidneys excrete potassium. The resulting rise in blood potassium is usually mild and clinically insignificant in people with healthy kidneys, but it can become dangerous in patients who already have impaired kidney function or are taking other medications that raise potassium.¹³ Routine electrolyte panels during a heparin drip usually catch this before it becomes a problem.

Bone loss is another concern, though it is relevant mainly to long-term use rather than a typical hospital stay of a few days. Unfractionated heparin given for weeks to months can decrease bone formation and increase bone breakdown. Studies in pregnant women on prolonged heparin therapy suggest that symptomatic vertebral fractures occur in up to about 3 out of every 100 patients on long-term treatment, and a much larger proportion experience measurable bone density loss.¹⁴ Low-molecular-weight heparins appear to carry substantially less bone risk than unfractionated heparin, which is one reason they are often preferred when anticoagulation is needed for extended periods.¹⁵

Heparin in Pregnancy

Pregnant patients who need anticoagulation are in a bind: the most common oral blood thinners cross the placenta and can cause birth defects, but blood clots during pregnancy are a serious threat. Heparin, whether unfractionated or low-molecular-weight, does not cross the placenta, making it one of the few anticoagulants considered safe for the fetus.¹⁶¹⁷ Both forms can also be used safely while breastfeeding.

In practice, most pregnant patients who need long-term anticoagulation are given low-molecular-weight heparin injections rather than a continuous IV drip, partly because of the bone loss concerns with prolonged unfractionated heparin described above. The IV drip does get used around delivery, however, because its short half-life allows the medical team to stop it and let the anticoagulant effect fade before labor or a cesarean section, reducing the risk of excessive bleeding during birth. After delivery, patients often transition back to a subcutaneous injection or an oral anticoagulant.

Why Heparin Over Newer Blood Thinners

Newer oral anticoagulants have become the standard for many outpatient clotting problems, which raises a fair question: why does the hospital still reach for an IV medication discovered over a century ago? The answer lies in control. A heparin drip can be started and stopped on the order of minutes, and its effect can be precisely measured with a blood draw. No oral anticoagulant offers that degree of real-time adjustability. For a patient heading to the operating room in a few hours, or someone whose clinical status is changing rapidly, that minute-to-minute control is irreplaceable.

Heparin also has the advantage of being reliably reversible with protamine. While newer drugs now have their own antidotes, heparin-protamine reversal has decades of clinical track record behind it. And because unfractionated heparin is cleared by the liver’s reticuloendothelial system rather than the kidneys, it does not accumulate unpredictably in patients with poor kidney function, a population where dosing oral anticoagulants can be tricky.¹

What the Experience Feels Like for Patients

If you or someone you know is put on a heparin drip, the practical reality involves an IV pump attached to a pole, frequent blood draws (often every six hours during dose adjustments), and restrictions on movement dictated partly by the IV line. The drug itself does not cause noticeable sensations for most people, unlike some medications that burn going in or cause flushing. The main inconveniences are the blood draws and the inability to wander far from the pump.

You will likely notice nurses checking your IV site for signs of bleeding, asking about new bruises, and watching your urine and stool color. These checks are routine, not a sign that something has gone wrong. You may also see your platelet count being tracked on a daily basis, particularly after the first few days, as part of surveillance for HIT. If your platelets drop or you develop new symptoms like skin changes near the IV site or new pain or swelling in a limb, tell the nursing staff immediately rather than waiting for the next scheduled check.

Most patients are on a heparin drip for somewhere between 24 hours and a few days, long enough to stabilize an acute clotting problem and overlap with an oral anticoagulant that takes longer to reach full effect. Extended courses of several weeks are uncommon outside of specific situations like certain mechanical heart valves or complicated clotting episodes. For those who do need longer anticoagulation, the transition to a subcutaneous injection or oral medication is the standard path out of the hospital.